Delivery Order SPE2DB25D3110-SPE2DB25FTELT
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,479.50 to AmerisourceBergen Drug Corp for the supply of Ibsrela 50 mg tablets in quantities of 60 units. This firm fixed-price, competitively awarded contract was issued on August 1, 2025, with an ultimate completion date of August 4, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,141.98 to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Ibsrela 50 mg tablets (60-count units). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded pharmaceutical procurement to support federal medical supply needs. The order is scheduled for completion by September 23, 2025, with performance taking place at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $6,909.82 to AmerisourceBergen Drug Corp for Ibsrela 50 mg tablets (60-count units) on September 3, 2025, with completion expected by September 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $14,453.80 to AmerisourceBergen Drug Corp for the supply of Ibsrela 50 mg tablets (60-count units) on September 8, 2025, with completion targeted for September 9, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a $3,431.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Ibsrela 50 mg tablets (60-count units). This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. Performance will be executed from the contractor's Conshohocken, Pennsylvania location,...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $26,193.92 by the Defense Logistics Agency on August 7, 2025, for the supply of Ibsrela 50 mg tablets in quantities of 60 units. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Ibsrela 50 mg tablets (60 tablets per unit) under a firm fixed-price contract valued at $26,774.18. This non-set-aside delivery order is scheduled for completion by August 29, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract valued at $3,784.00, with completion targeted for September 18, 2025. This is a competitively awarded, non-set-aside delivery order issued by the federal government's medical procurement division. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract valued at $21,030.84, with completion expected by August 21, 2025. This competitively awarded, non-set-aside delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $3,047.31 to AmerisourceBergen Drug Corp for 60 tablets of Ibsrela 50 mg on June 27, 2025. This competitive award, issued without set-aside provisions, is structured as a firm fixed price delivery order with an ultimate completion date of June 30, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen Drug Corp maintains its corporate office. This delivery order...
- SPE2DB25D3110Indefinite Delivery Contract
- SPE2DB25D3110-SPE2DB25FTELTDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $21,745.62 to AmerisourceBergen Drug Corp for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed price contract. The award was made on September 22, 2025, with an ultimate completion date of September 23, 2025, and no set-aside designation was applied. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceutical products and medical supplies to military and veteran healthcare systems. The company's extensive portfolio of competitively awarded federal contracts demonstrates its capability to fulfill diverse pharmaceutical needs across multiple therapeutic domains, supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through flexible contract vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.7k | 9/22/25 |